Download full release - University Hospitals Newsroom

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Cardiac surgery wikipedia , lookup

Jatene procedure wikipedia , lookup

Quantium Medical Cardiac Output wikipedia , lookup

Lutembacher's syndrome wikipedia , lookup

Pericardial heart valves wikipedia , lookup

Mitral insufficiency wikipedia , lookup

Aortic stenosis wikipedia , lookup

Transcript
Date
Contact:
May 11, 2017
Mike Ferrari
216-844-7239
[email protected]
News Release
Department of Marketing and
Communications
3605 Warrensville Center Road
Cleveland, OH 44122
University Hospitals announces first commercial implant in the U.S. of
The Evolut PRO transcatheter heart valve
UH first in Ohio to offer new generation of the self-expanding, recapturable heart valve
CLEVELAND – New surgical options are only as good as they make you feel once you leave
the operating room. One of the biggest post-operative issues with the usually sound transaortic
valve replacements (TAVR) was that the newly inserted valve allowed leakage that created poor
outcomes.
University Hospitals announced that its surgeons completed the first commercial implant in the
United States of the newly FDA approved TAVR valve called the CoreValve™ Evolut™ PRO for
the treatment of severe symptomatic aortic stenosis. Recently unveiled clinical data showed
high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics
for the self-expanding valve.
The Evolut PRO device features a unique valve design with an outer wrap that adds surface
area contact between the valve and the native aortic annulus to further advance valve sealing
performance. The biocompatible porcine pericardial tissue wrap, in addition to other design
elements, is incorporated to address the occurrence of blood leaking through the sides of the
valve.
“The fact that the UH structural heart team was elected as the first one in the U.S. to use this
new device commercially, definitely reflects our leadership on the field,” said Gui Attizzani, MD,
cardiologist and lead interventionalist who performed the maiden procedure. “The new design
and flexibility solves a problem created by post-operative leaking in previous generations of
valves used in TAVR.”
Built on the proven platform of the recapturable CoreValve Evolut R System, the Evolut PRO
valve includes a self-expanding nitinol frame with its supra-annular valve position that helps
achieve excellent performance while reducing PVL
The Evolut PRO System provides a greater opportunity to treat patients with smaller vessels
through the preferred transfemoral access route. The 23 mm, 26 mm and 29 mm sizes of the
Evolut PRO System are available for use in the United States. It is not available for use in
countries outside of the U.S.
TAVR is a nonsurgical procedure performed with local anesthesia in which a special catheter
(hollow tube) is threaded into a blood vessel through the groin and guided inside the heart. This
procedure enables the implantation of a new heart valve without the need of opening the chest
ultimately replacing a severely stenotic (narrow) aortic valve which delivers enhanced and
elongated quantity of life for patients.
UH is recognized as a high-volume Center of Excellence and was the first training site for the
minimalist, percutaneous conscious sedation TAVR approach for other centers in the U.S. UH
Cleveland Medical Center is recognized by the American Heart Association and other agencies
for their optimal transcatheter aortic valve replacement practices, as well as internationally, with
our physicians teaching this procedure all over the world.
The benefits of lighter sedation, minimal blood loss and cardiac complications are among the
benefits to the patients. Additionally, hospital stay is reduced and recovery and rehabilitation is
minimized.
Today TAVR is commercially approved by the FDA for moderate or higher surgical risk patients.
UH is one of the 45 sites in the US and the only hospital in Cleveland area exploring a clinical
trial for expanded indications for transcatheter aortic valve replacement for low surgical risk
patients.
###
About University Hospitals
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals,
more than 40 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio. The
system’s flagship academic medical center, University Hospitals Cleveland Medical Center, located on a 35-acre
campus in Cleveland’s University Circle, is affiliated with Case Western Reserve University School of Medicine.
The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top
children’s hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for
women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer
Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer,
pediatrics, women's health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive
health, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in
national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home
to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery &
Development. UH is the second largest employer in northern Ohio with 26,000 employees. For more information,
go to UHhospitals.org.